Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Cognition Therapeutics Inc. Common Stock
CGTX | US
1.09
USD0.11
11.75%
CGTX | US
About Cognition Therapeutics Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
15/04/2026
Close
1.09
Open
0.99
High
1.10
Low
0.98
Cognition Therapeutics Inc. a clinical-stage biopharmaceutical company engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812 an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease. The company is also developing COG0201 SHINE a randomized double-blind and placebo-controlled for mild-to-moderate AD and is in phase II clinical trial. Its product pipeline also includes CT2168 for Synucleinopathies; and CT2074 for dry age-related macular degeneration. The company was incorporated in 2007 and is headquartered in Purchase New York.
View LessCGTX | US
Risk
185.9
Sharpe
1.41
Luna's Score
57/100
Recommendation
Hold
Luna says (CGTX | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
113.9%1 month
185.9%3 months
122.7%6 months
104.4%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.86
Debt to equity
0.03
Debt to assets
0.02
Ent. to EBITDA
-0.44
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-58.61M
MarketCap
43.74M
MarketCap(USD)
43.74M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-108.31
Short ratio
1.04
Short perc.
1.91
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.35
Range1M
0.65
Range3M
0.96
Volumes: Market Activity
Rel. volume
0.69
Price X volume
1.12M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.44 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.86 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 122.70 | - | Riskier |
| Debt to Equity | 0.03 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 43.74M | - | Emerging |
